NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04659629 |
|
Recruitment Status :
Active, not recruiting
First Posted : December 9, 2020
Last Update Posted : December 2, 2022
|
Sponsor:
Neoleukin Therapeutics, Inc.
Collaborator:
Merck Sharp & Dohme LLC
Information provided by (Responsible Party):
Neoleukin Therapeutics, Inc.
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Active, not recruiting |
|---|---|
| Estimated Primary Completion Date : | May 2023 |
| Estimated Study Completion Date : | December 2024 |
| Submission Cycle | Results Submitted to ClinicalTrials.gov | Results Returned after Quality Control Review |
|---|---|---|
| 1 |
April 6, 2023 |